Months and Years	Overview
Oct, 2014	Founded Repertoire Genesis Inc.
Nov, 2014	Set up a laboratory in Osaka, Japan
Dec, 2014	Immune diversity analysis service was started
Jun, 2015	Signed a contract service intermediation agreement with Wako Pure Chemical Industries Ltd. (presently FUJIFILM Wako Pure Chemical Corporation) and designated it as our distributor in Japan
May, 2016	Set up a branch office in Tokyo
Apr, 2017	Expansion of Osaka Laboratory (Head Office)
Jun, 2017	A basic patent on immune diversity analysis was established in Japan (Japanese Patent No. 6164759)
Oct, 2017	Two patents were jointly filed with Hiroshima University on the complete replacement technique of T cell receptors that contribute to novel T cell therapy
Aug, 2018	A patent on biomarkers for ME/CFS was co-filed with the National Center of Neurology and Psychiatry
	Applied for a patent of amplification technology of TCR/BCR pair gene from a single cell
Oct, 2018	Expansion of Osaka Laboratory (Head Office)
Nov, 2018	Relocation of Tokyo Office
Mar, 2019	Osaka Laboratory acquired the international standard "ISO/IEC 17025: 2017" accreditation in the field of TCR/BCR repertoire analysis for the first time in the world
Sep, 2019	Concluded a comprehensive joint R&D agreement and capital alliance with Zenyaku Kogyo Co., Ltd.
Oct, 2019	Started a Collaborative Research Laboratory program named “Next Generation Development of Genome and Cellular Therapy Program” in the Department of Hematology and Oncology at Research Institute for Radiation Biology and Medicine, Hiroshima University
Mar, 2020	Concluded a non-exclusive Collaboration and Option to License Agreement with Cellectis SA. on the development of a TCR-T cell product against NY-ESO-1 with the TAL Nuclease technology for cancer immunotherapy
May, 2020	A basic patent on neoepitope analysis was established in Japan (Japanese Patent No.6710004)
Jun, 2020	Participation in the development project of a comprehensive evaluation method of COVID-19 virus antigen-specific immune responses for the selection of high-risk patients
	Signed a contracted research and development agreement with AMED to establish basic technology for manufacturing highly functional genome-edited T cells
Dec, 2021	A basic patent on TCR/BCR Repertoire Analysis was established in the US (US Patent No. 11203783)
May, 2022	Eurofins Scientific SE acquired a majority stake in our company and we became a member of the Eurofins Group
Sep, 2022	A patent for a new biomarker for cancer immunotherapy co-filed with Hyogo College of Medicine was granted in Japan (Japanese Patent No.7150280)
Jun, 2023	Participation in the development of the AMED project "Research on the development of a comprehensive evaluation method for pathogen antigen epitopes in preparation for disease X and its application to epidemic forecasting"